Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Edwards

Showing results (1201-1210 of 1,259) with videos related to

Pageof 126
Sort By:
Journal of Medicinal Chemistry|December 28, 2020
Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)Hengmiao Cheng, Suvi T M Orr, Simon Bailey, et al.
Pharmacological Reviews|August 16, 2023
International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily-Update 2023Thomas P Burris, Ian Mitchelle S de Vera, Isabelle Cote, et al.
British Journal of Cancer|March 29, 2017
Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association ConsortiumSuzanne C Dixon, Christina M Nagle, Nicolas Wentzensen, et al.
Journal of Medicinal Chemistry|March 14, 2017
Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFRSimon Planken, Douglas C Behenna, Sajiv K Nair, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 25, 2023
Identification of small-molecule protein-protein interaction inhibitors for NKG2DAaron A Thompson, Michael B Harbut, Pei-Pei Kung, et al.
Blood|June 21, 2024
Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemiasMin Chul Kwon, Jan Willem Thuring, Olivier Querolle, et al.
Ecology|August 6, 2019
FragSAD: A database of diversity and species abundance distributions from habitat fragmentsJonathan M Chase, Mario Liebergesell, Alban Sagouis, et al.
Journal of Medicinal Chemistry|January 18, 2014
Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinibQinhua Huang, Ted W Johnson, Simon Bailey, et al.
Cancer|March 6, 2019
Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special ConferenceRobert C Bast, Ursula A Matulonis, Anil K Sood, et al.
Cancer Research|April 6, 2007
Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancerSimon A Gayther, Honglin Song, Susan J Ramus, et al.
Pageof 126

Showing results (1201-1210 of 1,259) with videos related to

Sort By:
Pageof 126
Journal of Medicinal Chemistry|December 28, 2020
Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)Hengmiao Cheng, Suvi T M Orr, Simon Bailey, et al.
Pharmacological Reviews|August 16, 2023
International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily-Update 2023Thomas P Burris, Ian Mitchelle S de Vera, Isabelle Cote, et al.
British Journal of Cancer|March 29, 2017
Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association ConsortiumSuzanne C Dixon, Christina M Nagle, Nicolas Wentzensen, et al.
Journal of Medicinal Chemistry|March 14, 2017
Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFRSimon Planken, Douglas C Behenna, Sajiv K Nair, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 25, 2023
Identification of small-molecule protein-protein interaction inhibitors for NKG2DAaron A Thompson, Michael B Harbut, Pei-Pei Kung, et al.
Blood|June 21, 2024
Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemiasMin Chul Kwon, Jan Willem Thuring, Olivier Querolle, et al.
Ecology|August 6, 2019
FragSAD: A database of diversity and species abundance distributions from habitat fragmentsJonathan M Chase, Mario Liebergesell, Alban Sagouis, et al.
Journal of Medicinal Chemistry|January 18, 2014
Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinibQinhua Huang, Ted W Johnson, Simon Bailey, et al.
Cancer|March 6, 2019
Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special ConferenceRobert C Bast, Ursula A Matulonis, Anil K Sood, et al.
Cancer Research|April 6, 2007
Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancerSimon A Gayther, Honglin Song, Susan J Ramus, et al.
Pageof 126